Houstonians are struggling the most with work-related stress, WalletHub found. Photo via Getty Images

Stress is an unavoidable part of life, but a new report by WalletHub shows Houston residents are far more stressed out than any other city in Texas.

Houston ranked No. 18 out of 182 of the largest U.S. cities based on work, financial, family-related, and health and safety stress, according to WalletHub's "Most & Least Stressed Cities in America (2024)" report. 39 relevant metrics were considered in the report, including each city's job security, the share of households behind on bills within the last 12 months, divorce rates, crime rates, among others.

Houston was ranked the most stressed out city in Texas, but it's still far less stressed than many other U.S. cities. Cleveland, Ohio took first place as the most stressed city in America, followed by Detroit, Michigan (No. 2), Baltimore, Maryland (No. 3), Memphis, Tennessee (No. 4), and Gulfport, Mississippi (No. 5).

Out of the four main categories, Houstonians are struggling the most with work-related stress, ranking No. 13 nationally. The report found Houston has the No. 1 highest traffic congestion rate out of all cities in the report. But at least Houston drivers are solidly average, as maintained by a separate Forbes study comparing the worst drivers in America.

Houston workers can rejoice that they live in a city with a generally high level of guaranteed employment, as the city ranked No. 151 in the job security comparison. The city ranked No. 16 nationwide in the metric for the highest average weekly hours worked.

Houston fared best in the financial stress category, coming in at No. 72 nationally, showing that Houstonians aren't as worried about pinching pennies when it comes to maintaining a good quality of life. The city ranked No. 39 in the comparison of highest poverty rates.

Here's how WalletHub quantified Houston's stress levels:

  • No. 17 – Health and safety stress rank (overall)
  • No. 36 – Family stress rank (overall)
  • No. 63 – Unemployment rates
  • No. 81 – Percentage of adults in fair/poor health
  • No. 95 – Divorce rate
  • No. 96 – Percentage of adults with inadequate sleep

WalletHub analyst Cassandra Happe said in the report that living in particularly arduous cities can play a big role in how stressed a person is, especially when considering uncontrollable circumstances like family problems or work-related issues.

"Cities with high crime rates, weak economies, less effective public health and congested transportation systems naturally lead to elevated stress levels for residents," Happe said.

Happe advised that residents considering a move to a place like Houston should consider how the city's quality of life will impact their mental health, not just their financial wellbeing.

Other Texas cities that ranked among the top 100 most stressed cities in the U.S. are:

  • No. 20 – San Antonio
  • No. 38 – Laredo
  • No. 41 – Dallas
  • No. 47 – Corpus Christi
  • No. 61 – El Paso
  • No. 68 – Fort Worth
  • No. 71 – Brownsville
  • No. 75 – Arlington
  • No. 78 – Grand Prairie
  • No. 88 – Garland
The full report and its methodology can be found on wallethub.com

.

------

This article originally ran on CultureMap.

Roberta Schwartz is leading the innovation initiative at Houston Methodist. Courtesy of Houston Methodist

Meet the Houston Methodist executive at the helm of the new innovation-focused initiative

Featured Innovator

In an effort to be at the forefront of technology in the health care industry, Houston Methodist recently premiered its Center for Innovation, a group of leaders charged with finding new technologies for the hospital system for patients, physicians, and staff.

Roberta Schwartz — executive vice president, chief innovation officer, and chief executive officer of Houston Methodist Hospital — is at the helm of the initiative. After 17 years at Houston Methodist, Schwartz says she's seen the evolution of tech and is taking note of where the industry is going.

"I think we're an industry that is transforming itself. We're either going to be disrupted or we're going to do the disruption ourselves," Schwartz says. "There's nobody who knows health care better than we do, so if we're going to transform the industry, I want that transformation to come from the inside."

The hospital is instituting new pilot programs for tech advancements across the organization. Schwartz talks about the program and what she's excited about.

InnovationMap: Tell me about Houston Methodist's new Center for Innovation. How did it come about?

Roberta Schwartz: Methodist has always been an innovative institution. As we really saw the onset of a lot of disruption particularly in digital technology, we had already upgraded our electronic medical records. What we saw was with the onslaught of technology in other fields, they were figuring out how to layer pieces on top of our electronic medical record system to make that information usable — more patient friendly and smarter. As we watched these technologies come in, we found that there were a number of us within the organization that were just talking about it all the time and watching how we could really revolutionize the way we worked by embracing these new technologies. So, it probably started about 18 months ago where we found a group of us talking all the time, emailing articles, and figuring out how to hitch up our budgets for new technologies. Our CEO, Marc Boom was so supportive of us. We started meeting every other week for an hour. We called our group the DIOP — the digital innovation obsessed people. That's how it began.

IM: How did DIOP become the Center for Innovation?

RS: We spoke with our CFO and CEO. They said go ahead and provided us with some budget dollars for some pilots. We have now embraced a series of pilots in different areas of need. DIOP became formalized early this year and the Center for Innovation was born. We're now looking at a vision statement of how we can transform almost every aspect of our patient, physician, and administrative experience to make everyone's lives easier and better.

IM: What new innovative efforts are you most excited about introducing to the hospital?

RS: On the patient engagement front, we partner with a platform that breaks up bite-sized content that allows you in text form through — videos or two-way communication — so that we can engage with you before you even make a phone call to our office. For instance, after a visit we can ask you, "how bad is your pain on a scale of 1 to 10," and if you respond "10" we're going to call you before you call the office and have to press one, two, or three on our call board.

A second area we're excited about is a way to text back and forth with your doctor's office. We're changing to a much more modern communication style.

We're also changing how we recruit. We have a chatbot that's available 24/7. We find that we are communicating with night nurses at 1 am asking about benefits. A lot of the people we are trying to recruit are working at night when we don't have HR staff in the office all night long.

We are also looking robotic process automation and trying to take some of the menial work away from our staff so we can get them closer to the bedside or on more tasks.

Methodist went mobile. Our app is online — you can do virtual care, urgent care, or second opinion. Soon, we'll have virtual behavioral health and nutrition. You can also request an appointment.

IM: How is the technology changing the footprint of the hospital?

RS: We want to make Houston Methodist services available all over the country and the world, where it's appropriate. We're going to serve primarily Houston, but if we want to help those institutions in a more rural area, send them to us when appropriate, but for those who can stay at home and in bed, we want to keep them where they are and still provide them with the same level of care.

IM: With the 100-year anniversary of Houston Methodist, what do you hope to put in place for the next 100 years?

RS: We're an organization built on the pillars of success, and we constantly evolve. I can't even tell you where we'll be in a hundred years. I can tell you is that in a few years every type of ease of interaction that you have with Alexa and Amazon, that you have that type of interaction with your hospital.

I'm thrilled to be on this journey, and we're loving it.

------

Portions of this interview have been edited.

Houston-based iCRYO has a few Texas franchise locations expected to open in 2019,and more coming nationwide. Courtesy of iCRYO.

Houston-based cryotherapy chain grows its national presence

Cold news

A Houston entrepreneur has taken his cryotherapy and wellness brand and franchised it from its origin in League City to upstate New York. But, that's only the beginning.

The brand, iCRYO, currently has four locations in the Houston area and one in New York, and has four more coming to the Dallas-Fort Worth area, Austin, and another upstate New York location. But that's only the start, says co-founder and COO, Kyle Jones.

Jones says he was among the first in the country to see the potential for cryotherapy as a retail business. He was managing a physical therapy clinic, and they added a cryotherapy machine as a treatment for patients. Jones says he was blown away by how fast the patients were recovering — some even accelerating their healing process by 50 percent.

"I told my boss that we needed to scale this thing. This is a real business, not just an add-on for a PT clinic," Jones says.

As patients overwhelmed the small operation and as retail cryotherapy centers began popping up, Jones decided to branch out on his own. He was 24 at the time.

In 2015, he opened his first location of iCRYO in League City. Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones says. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

He teamed up with equipment manufactures and professionals at the gas companies that handle the liquid nitrogen cryotherapy uses and they created a cloud-based certification platform for cryotherapy. He still uses that program with all iCRYO employees — everyone from the owner to the technician has to pass with a 90 percent and above.

After two years of business and settling on the company's marketing, Jones started to franchise. He sold eight locations in Houston, three have opened already. The first Austin iCRYO location plans to open in May, and three Dallas-area locations are also expected to deliver in 2019.

Jones says he is still actively looking for new franchisees, and is in talks to sell franchise rights to the entire states of Florida and Georgia, more locations in New York, San Antonio, and other cities scattered around. It's an intriguing market to franchisees, Jones says, because there's just not that much competition yet and the technology has so much potential.

"The more that people find out about it and research it, the crazier it's going to get," Jones says. "There's just no peak of people wanting to feel better."

Saudi Arabian representatives met at Houston-based Celltex Therapeutics Corp.'s office earlier this month to finalize a memorandum of understanding. Courtesy of Celltex

Houston biotech company plans expansion into Saudi Arabian market

On the move

A Houston company that uses stem cell technology to treat patients suffering from degenerative diseases is taking its patented technology to another continent.

Celltex Therapeutics Corp. has entered a memorandum of understanding with Saudi Arabia's Research Products Development Company. As a part of the partnership solidified by the MOU, Celltex will open an office in Riyadh, Saudi Arabia, later this year. The new office will aid the commercialization of Celltex's technology and expand the company's presence to Saudi Arabia.

"We are honored to forge a relationship with Saudi Arabia," says David G. Eller, CEO and chairman of Celltex, in a release. "Our collaboration with this first-rate global cohort furthers our commitment to initiating breakthroughs in regenerative medicine, and our presence in Riyadh will further expand our opportunities to improve the quality of life of those in need."

The MOU is a part of the country's effort to diversify the economy that's been dominated by oil and gas, the release says. As a part of Saudi Arabia's National Industrial Development and Logistic Program, Celltex and other United States companies were invited to Riyadh to sign MOUs in January, which resulted in billions of dollars in Saudi investment, per the release.

On February 4, the two parties reconvened at Celltex's office in Houston. The group included top Saudi dignitaries, Abdulmohsen Almajnouni, CEO of RPDC, as well as others.

"We are excited to explore business opportunities with Celltex, a biotechnology company with the innovative proprietary technology, patents and know-how for the cultivation and therapeutic application of stem cells," Almajnouni says in the release.

Celltex currently extracts patients' stem cells at various partner facilities across the United States, but implementation happens at a hospital in Mexico, due to FDA regulations and red tap. However, Eller doesn't foresee this being the process forever.

"We have very good relations with the US FDA," he says in an InnovationMap article. "They are very interested in what we know. Our approach is really is very progressive and we've grown every year."

The company's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

From a locally sourced meal service company to stem cell research and a balance measuring device, this week's innovators are ones to know in the health industry. Courtesy photos

3 Houston health-focused innovators to know this week

Who's who

More and more Americans are focusing on their health, from eating right to experimenting with new treatments or devices. These three Houston innovators are riding the coattails of this health-focused movement with their startups. With advances in technology and the movement only growing faster and faster, you'd better keep your eye on these Houston innovators.

Marla Murphy, founder of The Blonde Pantry

Courtesy of The Blonde Pantry

Marla Murphy didn't feel like she was doing enough to promote health and wellness with her platform, The Blonde Pantry. So, she expanded it to incorporate locally sourced produce and easy-to-make recipes she gets ready every weekend to deliver to her members by Monday.

"It's not about selling meals and moving on, I want this to be a lifestyle company that is really founded and has deep roots in Houston," says Murphy in a InnovationMap story.

Murphy tells InnovationMap that in the next year she hopes to expand into the retail space and find a bigger commercial kitchen to function as their own. She also hopes to partner with companies outside of food and continue to nourish lives in someway.

David Eller, chairman, co-founder and CEO of Celltex

Courtesy of Celltex

Stem cell treatment is personal to David Eller, chairman, co-founder and CEO of Celltex. Eller had the treatment in hopes of resolving pain from a college football injury.

"I would go to work and put four to six Advil in my pocket," Eller says in an InnovationMap story about Celltex's technology. Within months, he stopped needing those pills.

Houston-based Celltex tracks its progress with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

Katharine Forth, founder and CEO of Zibrio

Courtesy of Zibrio

Katharine Forth has used a technology she developed with her colleague at NASA to measure balance in astronauts to create a device that any terrestrial human can now use from the comfort of their own homes.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says in an InnovationMap article about Zibrio, The Balance Company. Zibrio, The Balance Company.

Zibrio is now a finalist for the 2019 SXSW Pitch in the health and wearables category and will take its balance technology to the stage in March.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.